Pegcetacoplan Long Term Safety and Efficacy Extension Study

This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Apellis Pharmaceuticals (APLS) is the sponsoring company for this trial. BiotechSign currently grades this company C (50/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.